Wuhan No.1 Hospital, Wuhan, 430022, Hubei, China.
Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):2849-2876. doi: 10.1007/s00210-023-02840-8. Epub 2023 Nov 22.
A comprehensive overview of CD44 (CD44 Molecule (Indian Blood Group)), a cell surface glycoprotein, and its interaction with hyaluronic acid (HA) in drug resistance mechanisms across various types of cancer is provided, where CRISPR/Cas9 gene editing was utilized to silence CD44 expression and examine its impact on cancer cell behavior, migration, invasion, proliferation, and drug sensitivity. The significance of the HA-CD44 axis in tumor microenvironment (TME) delivery and its implications in specific cancer types, the influence of CD44 variants and the KHDRBS3 (KH RNA Binding Domain Containing, Signal Transduction Associated 3) gene on cancer progression and drug resistance, and the potential of targeting HA-mediated pathways using CRISPR/Cas9 gene editing technology to overcome drug resistance in cancer were also highlighted.
提供了对 CD44（CD44 分子（印度血型））的全面概述，这是一种细胞表面糖蛋白，以及它与透明质酸（HA）在各种类型癌症中的耐药机制中的相互作用，其中利用 CRISPR/Cas9 基因编辑沉默 CD44 表达，并研究其对癌细胞行为、迁移、侵袭、增殖和药物敏感性的影响。还强调了 HA-CD44 轴在肿瘤微环境（TME）传递中的重要性及其在特定癌症类型中的意义、CD44 变体和 KHDRBS3（KH RNA 结合域包含、信号转导相关 3）基因对癌症进展和耐药性的影响，以及利用 CRISPR/Cas9 基因编辑技术靶向 HA 介导的途径克服癌症耐药性的潜力。
